Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) is a multifactorial disorder associated with neuroinflammation, elevated oxidative stress, lipid alterations as well as amyloid-deposits and the formation of neurofibrillary tangles. Ibuprofen, a globally used analgesic, is discussed to influence disease progression due to its anti-inflammatory effect. However, changes in lipid-homeostasis induced by Ibuprofen have not yet been analyzed. Here we investigate the effect of Ibuprofen on lipid classes known to be associated with AD. Ibuprofen treatment leads to a significant increase in phosphatidylcholine, sphingomyelin and triacylglyceride (TAG) species whereas plasmalogens, which are highly susceptible for oxidation, were significantly decreased. The observed alterations in phosphatidylcholine and sphingomyelin levels in presence of Ibuprofen might counteract the reduced phosphatidylcholine- and sphingomyelin-levels found in AD brain tissue with potential positive aspects on synaptic plasticity and ceramide-induced apoptotic effects. On the other hand, Ibuprofen leads to elevated TAG-level resulting in the formation of lipid droplets which are associated with neuroinflammation. Reduction of plasmalogen-levels might accelerate decreased plasmalogen-levels found in AD brains. Treatment of Ibuprofen in terms of lipid-homeostasis reveals both potentially positive and negative changes relevant to AD. Therefore, understanding the influence of Ibuprofen on lipid-homeostasis may help to understand the heterogeneous results of studies treating AD with Ibuprofen. • SH-SY5Y cells treated with Ibuprofen (IBU) revealed significant lipidome changes with relevance for Alzheimer’s disease (AD). • IBU incubation increased phosphatidylcholine and sphingomyeline levels, that were found to be decreased in AD brains. • Plasmalogens, known for their antioxidant properties, were reduced upon IBU treatment. • Triacylglyceride levels, major component of lipid droplets, accumulating in neurons in AD, were elevated after IBU treatment.

What this study adds

Evidence grade: Low

In laboratory lipid studies, ibuprofen raised some lipids that are low in Alzheimer's brain tissue but also raised triglycerides linked to neuroinflammation and lowered plasmalogens, which are already reduced in Alzheimer's brains. This means ibuprofen's effects on brain lipids are mixed, with both potentially helpful and potentially harmful changes, so it cannot be assumed to slow or prevent the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Radermacher, J., Erhardt, V. K. J., Walzer, O., Haas, E. C., Kuppler, K. N., Zügner, J. S. R., et al. (2025). Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2025.117969

Vancouver

Radermacher J, Erhardt VKJ, Walzer O, Haas EC, Kuppler KN, Zügner JSR, et al. Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease. Biomedicine & Pharmacotherapy. 2025. doi:10.1016/j.biopha.2025.117969. PMID: 40073745.

BibTeX

@article{radermacher2025-40073745,
  author  = {Radermacher, Juliane and Erhardt, Vincent Konrad Johannes and Walzer, Oliver and Haas, Elodie Christiane and Kuppler, Konstantin Nicolas and Zügner, Jill Sven René and Lauer, Anna Andrea and Hartmann, Tobias and others},
  title   = {{Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease}},
  journal = {Biomedicine \& Pharmacotherapy},
  year    = {2025},
  doi     = {10.1016/j.biopha.2025.117969},
  pmid    = {40073745},
  url     = {https://doi.org/10.1016/j.biopha.2025.117969}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In laboratory lipid studies, ibuprofen raised some lipids that are low in Alzheimer's brain tissue but also raised triglycerides linked to neuroinflammation and lowered plasmalogens, which are already reduced in Alzheimer's brains. This means ibuprofen's effects on brain lipids are mixed, with both potentially helpful and potentially harmful changes, so it cannot be assumed to slow or prevent the disease.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 35 of 100.35 of 100 points earned65 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Biomedicine & Pharmacotherapy)
Journal's citation record 2 / 4 Biomedicine & Pharmacotherapy: journal h-index 227 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Marcus O.W. Grimm: h-index 42 (OpenAlex, whole career)
Institution's track record 0 / 3 Saarland University: institution h-index 560 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40073745)
Free to read 2 / 2 Free to read
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Inflammation and the immune system from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →